TAIPEI, Taiwan, Aug. 30, 2015 /PRNewswire/ -- TWi
Pharmaceuticals, Inc. ("TWi") (stock ticker: 4180.TT) announced
that its President and CEO Ms. Tina
Guilder will resign from her current roles. Chairman
Dr. Chih-Ming Chen will become
interim President and CEO, leading TWi in its aim to maintain its
growth momentum.
Dr. Chen is the founder of TWi and in his role as Chairman has
historically been the chief architect of TWi's strategy.
Taking the CEO role personally, he will focus on operating
strategies, making precise product selections, motivating top
management and all employees, and integrating the business groups'
resources to strengthen the core competencies of TWi.
TWi believes, that the sales strategies for its commercialized
generic products will benefit from Dr. Chen's experience, including
successfully establishing generic pharmaceutical businesses in the
U.S. market and his deep relationships in the industry. Dr.
Chen will also lead the Company in its continued execution and
strengthening of its research and development, business strategies
and further promotion of its business expansion in the United States and international generics
markets. TWi believes that, under Dr. Chen's leadership, it
will maintain its growth momentum.
About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical
company based in Taipei, Taiwan,
focusing on the development of high-entry-barrier generic
prescription products ranging from oral controlled release dosage
form to novel drug delivery systems including the utilization of
nanoparticles, transdermal, and oral delivery systems.
Leveraging its internal research and development
capabilities, together with operational flexibility, process
development, manufacturing and regulatory expertise, TWi
Pharmaceuticals concentrates on products and technologies that
present significant barriers to entry or offer Paragraph IV
first-to-file or first-to-market opportunities in the United States. For more information
of TWi Pharmaceuticals, please visit www.twipharma.com.
Contact:
Eric Lin
Investor Relations
Tel: +886-2-2657-3350 ext. 407
Email: eric.lin@twipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/twi-pharmaceuticals-president--ceo-ms-tina-guilder-will-resign-from-her-current-roles-and-chairman-dr-chih-ming-chen-will-become-interim-president--ceo-leading-the-company-in-its-continued-efforts-to-develop-high-entry-barrie-300134991.html
SOURCE TWi Pharmaceuticals, Inc.